Waters Corporation WAT
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Waters Corporation (WAT) Price to free cash flow
As of 25 September 2026, Waters Corporation (WAT) trades at a price to free cash flow of 116×. Over the past ten years it has ranged from 0.0× (December 2024) to 136× (May 2026); the current reading is higher than 99% of that period. That is above the Diagnostics & Research industry median of 34.0× and above the Healthcare sector median of 19.5×.
Price to free cash flow, daily
Annual
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 44.5× | 25.36% |
| FY2024 | 35.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 48.4× | 22.18% |
| FY2021 | 39.6× | 37.36% |
| FY2020 | 28.8× | (13.42%) |
| FY2019 | 33.3× | 15.46% |
| FY2018 | 28.9× | 12.20% |
| FY2017 | 25.7× | 24.98% |
| FY2016 | 20.6× | (11.16%) |
Quarterly
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 100× | (4.88%) |
| Mar 2026 | 106× | 137.19% |
| Dec 2025 | 44.5× | 50.27% |
| Sep 2025 | 29.6× | (11.70%) |
| 42 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 19.4× |
| IQV IQVIA Holdings Inc. compare | 19.9× |
| IDXX IDEXX Laboratories, Inc. compare | 33.1× |
| MTD Mettler-Toledo International, Inc. compare | 35.2× |
| A Agilent Technologies, Inc. compare | 38.4× |
| ILMN Illumina, Inc. compare | 44.9× |
| WAT Waters Corporation | 116× |
| NTRA Natera, Inc. compare | 702× |
| Diagnostics & Research industry median | 34.0× |
| Healthcare sector median | 19.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on WAT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement